What’s New in Respiratory Space This Week
Catch the latest lung and respiratory health headlines in under 5 minutes! From gene editing milestones to the first-ever biologic approval for COPD in South Korea, cutting-edge advancements in clinical research and therapeutic innovation.
🌟 AATD Gene Therapy Milestone: Beam-302 corrects 91 percent of circulating AAT protein at Day 28, with Z-AAT levels reduced by 79 percent. A potential one-time curative option for alpha-1 antitrypsin deficiency moves closer to reality.
👶 Cystic Fibrosis Access Expanded: Kaftrio’s label now includes children aged two and older with non-class I CFTR mutations, potentially benefiting 4,000 more patients across the EU.
💉 Biologic Breakthrough in COPD: Dupixent becomes the first biologic approved in South Korea for COPD, showing a 30 percent reduction in exacerbations and significant improvements in lung function and quality of life.
🌬️ INNA-051 Advances for Older Adults: This intranasal immune modulator activates defense pathways within 8 hours in adults aged 66–80 and shows reduced influenza spread in aged mice—Phase 2 set for late 2025.
📢 Stay Ahead in Lung and Respiratory Health Research!
✅ Like, share, and subscribe for weekly updates on lung and respiratory health
#AATD #CF #COPD #LungHealth #GeneTherapy #BeamTherapeutics #KAFTRIO #Dupixent #INNA051 #RespiratoryResearch #Biologics #Immunology #PharmaUpdates #LucidQuest #ClinicalTrials #HealthcareInnovation #RespiratoryMedicine #LungCare